Pharm Exec17h
Q&A: Gain Therapeutics CEO Discuss AI-Driven Drug Discovery, Strategic Growth Plans
Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial ...
N.I.H. Research Grants Lag $1 Billion Behind Last Year’s
After weeks of disruption to scientific federal grants, the National Institutes of Health has fallen behind in funding ...
IN8bio, Inc: IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML
February 14, 2025 - IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented ...
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025--Interim clinical study update to be presented in ...
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update
Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues Promising Data, including a 59% Stable ...